RenovoRx Inc (RNXT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.39+0.84%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RNXT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue accelerating commercial adoption of RenovoCath to drive revenue growth and exceed prior full-year revenue guidance for 2026.
Stated as a priority in 3 of last 3 quarters. Revenue grew from $1.1 million in full-year 2025 to $563,000 in 2026-Q1 and $909,000 in 2026-Q2 (61% sequential growth). Management raised 2026 full-year revenue guidance from $3.0-$4.0 million to $3.75-$4.25 million, reflecting accelerating commercial adoption and record revenue quarters. The trajectory is delivering against the stated growth priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Raising and tightening full-year 2026 revenue guidance to $3.75M to $4.25M”
“Reiterating full year 2026 revenue guidance of $3 to $4 million”
“For the year ending December 31, 2025, the Company generated $1.1 million in revenue”
Grow the number of active commercial cancer center customers using RenovoCath to drive recurring revenue and commercial momentum.
Stated as a priority in 2 of last 2 quarters. Active commercial cancer centers increased from 16 in 2026-Q1 to 21 in 2026-Q2, a 31% increase. Management remains on track to meet or exceed the target of 36 centers by year-end 2026. The trajectory shows delivering progress toward this expansion goal.
“Ended Q2 with 21 active commercial cancer center customers, up 30% from 16 in Q1”
“Expanded active commercial cancer center customers to 16 with growing sales pipeline”
Achieve full enrollment in the Phase III TIGeR-PaC trial evaluating intra-arterial gemcitabine delivery via RenovoCath for LAPC treatment.
Stated as a priority in 2 of last 2 quarters. The Phase III TIGeR-PaC trial reached full enrollment by mid-2026 with 114 patients randomized and 78 of 86 required events observed by August 2026. Completion is expected in first half 2027 with topline data in second half 2027. Management is delivering on this enrollment milestone.
“Phase III TIGeR-PaC trial reached full enrollment; completion expected first half 2027”
“TIGeR-PaC trial advancing toward completion with full enrollment expected in June 2026”
Manage cash resources prudently to ensure operational funding through the second half of 2027.
Stated as a priority in 2 of last 2 quarters. Cash and cash equivalents decreased from $12.4 million in 2026-Q1 to $9.5 million in 2026-Q2, reflecting disciplined capital deployment. Management affirms these resources are sufficient to fund operations into the second half of 2027. The trajectory shows prudent cash management aligned with stated funding goals.
“Cash and cash equivalents approximately $9.5 million as of June 30, 2026”
“Ended Q1 with $12.4 million in cash, sufficient to fund operations into at least H2 2027”
Continue accelerating commercial adoption and revenue growth to achieve raised full-year 2026 revenue guidance of $3.75M to $4.25M.
Over the trailing year it converted 1.11x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, real (inflation-adjusted) rates, the US dollar, long-term interest rates, Fed net liquidity (low R² over the window).
8 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.